Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211471 · ClinicalTrials.gov registry record · Phase 2
Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).
A Phase 2 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00211471 is a Phase 2 study that was terminated before completion, run by Manhattan Eye, Ear & Throat Hospital.
The verdict
NCT00211471, a Phase 2 study, was terminated before completion, sponsored by Manhattan Eye, Ear & Throat Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
To provide use of Anecortave Acetate Sterile Suspension of 15mg for a series of five patients with rubeosis iridis. Rubeosis iridis refers to neovascularization of the iris. It is caused by a number of conditions which include, but are not limited to severe diabetic retinopathy, central retinal vein occlusion, chronic inflammation, and infection. Anecortave acetate is an angiostatic, experimental drug that is being tested to prevent the growth of blood vessels under the retina in patients with age-related macular degeneration (AMD). Therefore, it is logical to apply the usage of Anecortave to patient's with rubeosis iridis in order to reduce the neovascularization stimulus and cause the regression of the abnormal iris vessels.
Interventions
- DRUG anecortave acetate
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-03 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00211471
The ClinicalTrials.gov registry entry for NCT00211471 describes a study currently listed as terminated, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Manhattan Eye, Ear & Throat Hospital, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which anecortave acetate is the first listed.
NCT00211471 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00211471 about?
NCT00211471 is a clinical study titled "Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.).". To provide use of Anecortave Acetate Sterile Suspension of 15mg for a series of five patients with rubeosis iridis. Rubeosis iridis refers to neovascularization of the iris. It is caused by a number of conditions which include, but are not limited to severe diabetic retinopathy, central retinal vein...
What is the current status of trial NCT00211471?
This trial is currently terminated. It is a Phase 2 study. The study started on 2002-03. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00211471?
The interventions under investigation include: anecortave acetate (DRUG).
Who is sponsoring clinical trial NCT00211471?
This trial is sponsored by Manhattan Eye, Ear & Throat Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.